Edition:
United States

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

18.15USD
23 Feb 2018
Change (% chg)

$0.26 (+1.45%)
Prev Close
$17.89
Open
$17.92
Day's High
$18.16
Day's Low
$17.31
Volume
945,854
Avg. Vol
943,361
52-wk High
$18.30
52-wk Low
$6.74

Chart for

About

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its... (more)

Overall

Beta: 1.83
Market Cap(Mil.): $3,576.05
Shares Outstanding(Mil.): 197.03
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 195.87 16.59
EPS (TTM): -- -- --
ROI: -- -0.71 35.07
ROE: -- -3.37 17.79

Array melanoma drugs show significant survival versus Roche drug in study

A combination of experimental drugs from Array BioPharma Inc kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine, according to data from a late stage study released on Tuesday.

Feb 06 2018

UPDATE 1-Array melanoma drugs show significant survival vs Roche drug in study

Feb 6 A combination of experimental drugs from Array BioPharma Inc kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine, according to data from a late stage study released on Tuesday.

Feb 06 2018

BRIEF-Array Biopharma Q2 Loss Per Share $0.17

* ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF FISCAL 2018

Feb 06 2018

Array melanoma drugs show significant survival vs Roche drug in study

Feb 6 A combination of experimental drugs from Array BioPharma Inc kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine, according to data from a late stage study released on Tuesday.

Feb 06 2018

AstraZeneca is sued by Array BioPharma over cancer drug royalties

NEW YORK Array BioPharma Inc on Thursday sued AstraZeneca AB, accusing the pharmaceutical company of refusing to pay required royalties for a cancer drug after entering into an $8.5 billion collaboration with Merck & Co.

Feb 01 2018

AstraZeneca is sued by Array BioPharma over cancer drug royalties

NEW YORK, Feb 1 Array BioPharma Inc on Thursday sued AstraZeneca AB, accusing the pharmaceutical company of refusing to pay required royalties for a cancer drug after entering into an $8.5 billion collaboration with Merck & Co.

Feb 01 2018

BRIEF-Array Biopharma Says Its partner Seeks Withdrawal of Marketing Authorization Applications For Binimetinib Monotherapy in EU, Switzerland And Australia

* ARRAY BIOPHARMA SAYS PIERRE FABRE MEDICAMENT, REQUESTED THAT MARKETING AUTHORIZATION APPLICATIONS FOR BINIMETINIB MONOTHERAPY BE WITHDRAWN

Jan 23 2018

BRIEF-Aslan Pharmaceuticals buys full global commercial rights for Varlitinib

* ASLAN PHARMACEUTICALS ACQUIRES FULL GLOBAL COMMERCIAL RIGHTS FOR VARLITINIB FROM ARRAY BIOPHARMA

Jan 03 2018

BRIEF-Array BioPharma Announces Strategic Collaboration With Pfizer

* ARRAY BIOPHARMA ANNOUNCES STRATEGIC COLLABORATION WITH PFIZER

Dec 19 2017

BRIEF-Array - In Exchange For $126.06 Million 3.00% Convertible Senior Notes Co Issued 2024 $126.06 Million Notes

* ARRAY BIOPHARMA - ‍ON DEC 1, IN EXCHANGE FOR $126.06 MILLION OF 3.00% CONVERTIBLE SENIOR NOTES DUE 2020 CO ISSUED 2024 NOTES OF $126.06 MILLION

Dec 04 2017

Competitors

Earnings vs. Estimates